{"id":"W2065235857","doi":"10.1111/apt.12499","title":"Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from <scp>CHARM</scp> and <scp>ADHERE</scp>","year":2013,"lang":"en","type":"article","venue":"Alimentary Pharmacology & Therapeutics","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":113,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"UCB Pharma; Relypsa; Takeda Oncology; Merck Sharp and Dohme; Genentech; Norgine; Astellas Pharma; Eisai; Ironwood Pharmaceuticals, Incorporated; Therakos; AbbVie; Novo Nordisk; Teva Pharmaceutical Industries; Gilead Sciences; Procter and Gamble; Atlantic Healthcare; Amgen; ActoGeniX; Sanofi; Otsuka America; Celgene; Pfizer; Biogen; GlaxoSmithKline; Tillotts Pharma; Shire; Orexigen Therapeutics; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Adalimumab; Medicine; Crohn's disease; Adverse effect; Internal medicine; Clinical endpoint; Surgery; Maintenance therapy; Clinical trial; Gastroenterology; Disease; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008996479,0.0007596174,0.002255225,0.0004641181,0.0006262148,0.0009320502,0.0008264998,0.001392845,0.002642432],"category_scores_gemma":[0.006040999,0.0003761562,0.002451366,0.0007063019,0.0006054228,0.0006663764,0.0005822959,0.001993967,0.000765343],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005844842,"about_ca_system_score_gemma":0.0009006857,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001387406,"about_ca_topic_score_gemma":0.002228088,"domain_scores_codex":[0.9959574,0.002117357,0.0005570781,0.0003072284,0.0007152315,0.0003456236],"domain_scores_gemma":[0.9879139,0.004455272,0.003345818,0.001905479,0.001172939,0.001206616],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.7253362,0.009693456,0.06311816,0.004448066,0.009334797,0.0003818949,0.0006302944,0.001599948,0.01154585,0.0001671264,0.008801583,0.1649427],"study_design_scores_gemma":[0.1549746,0.2682934,0.5335748,0.0007533596,0.009139063,0.001367219,0.0002312114,0.0009274544,0.006291102,0.0002373012,0.02403775,0.0001726801],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9745628,0.01524166,0.0004902805,0.0003854507,0.00009367113,0.0007598335,0.005372221,0.00006724383,0.003026873],"genre_scores_gemma":[0.9810988,0.004926917,0.0006816877,0.0006610269,0.0002033857,0.000611999,0.009809897,0.00002870854,0.001977627],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008996479,"threshold_uncertainty_score":0.04757845,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0230151932692611,"score_gpt":0.2933277874489523,"score_spread":0.2703125941796912,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}